A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL

Leukemia

Volumn 22, Issue 7, 2008, Pages 1456-1459

  Best, O G ^a   Gardiner, A C ^a   Majid, A ^b   Walewska, R ^b   Austen, B ^c   Skowronska, A ^c   Ibbotson, R ^a   Stankovic, T ^c   Dyer, M J S ^b   Oscier, D G ^a  

^a ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^b MRC TOXICOLOGY UNIT   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATM PROTEIN; ETOPOSIDE; NUTLIN 3; PROTEIN P21; PROTEIN P53;

CANCER RESISTANCE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DRUG EXPOSURE; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE LOSS; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; LETTER; MONOTHERAPY; PRIORITY JOURNAL; PROCESS DEVELOPMENT; PROTEIN EXPRESSION; RELIABILITY; SENSITIVITY ANALYSIS;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; DNA-BINDING PROTEINS; ETOPOSIDE; GENES, P53; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MUTATION; PIPERAZINES; PROTEIN-SERINE-THREONINE KINASES; TUMOR SUPPRESSOR PROTEINS;

EID: 47549091008     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/sj.leu.2405092     Document Type: Letter

References (8)

1. Oscier DG, Wade R, Orchard J, Davis Z, Best G, Morilla A et al. Prognostic factors in the UK LRF CLL4 trial. Blood (ASH Annual Meeting Abstracts) 2006; 108: 299.
2. Byrd JC, Gribben JG, Peterson BL, Grever MR, Lozanski G, Lucas DM et al. Select high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
3. Austen B, Powell JE, Alvi A, Edwards I, Hooper L, Starczynski J et al Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood 2005; 106: 3175-3182.
4. Austen B, Skowronska A, Baker C, Powell JE, Gardiner A, Oscier D et al. Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol 2007; 25: 5448-5457.
5. Carter A, Lin K, Sherrington PD, Pettitt AR. Detection of p53 dysfunction by flow cytometry in chronic lymphocytic leukaemia. Br J Haematol 2004; 127: 425-428.
6. Carter A, Lin K, Sherrington PD, Atherton M, Pearson K, Douglas A et al. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia. Leukemia 2006; 20: 737-740.
7. Jones GG, Carter A, Pettitt AR, Sherrington PD. The arginine-encoding variant of the p21 (CDKN1A, p21WAF, Cip1) codon 31 polymorphism is over-represented in patients with CLL and is associated with failure of p21 induction following irradiation. Leuk Lymphorna 2005; 46 (Suppl 1): S56.
8. Bromidge T, Lowe C, Prentice A, Johnson S. p53 intronic point mutation, aberrant splicing and telomeric associations in a case of B-chronic lymphocytic leukaemia. Br J Haematol 2000; 111: 223-229.